Visionary Wealth Advisors Decreases Holdings in Pfizer Inc. (NYSE:PFE)

Visionary Wealth Advisors reduced its stake in shares of Pfizer Inc. (NYSE:PFE) by 1.3% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 210,828 shares of the biopharmaceutical company’s stock after selling 2,832 shares during the period. Visionary Wealth Advisors’ holdings in Pfizer were worth $6,070,000 at the end of the most recent reporting period.

A number of other large investors have also bought and sold shares of the company. Clifford Swan Investment Counsel LLC raised its holdings in Pfizer by 4.7% during the 4th quarter. Clifford Swan Investment Counsel LLC now owns 417,070 shares of the biopharmaceutical company’s stock valued at $12,007,000 after acquiring an additional 18,611 shares during the period. Adage Capital Partners GP L.L.C. increased its position in shares of Pfizer by 40.5% during the third quarter. Adage Capital Partners GP L.L.C. now owns 4,739,672 shares of the biopharmaceutical company’s stock valued at $157,215,000 after buying an additional 1,365,295 shares during the period. LifePlan Financial LLC purchased a new stake in shares of Pfizer in the fourth quarter worth about $255,000. Cantor Fitzgerald Investment Advisors L.P. bought a new position in shares of Pfizer in the fourth quarter valued at approximately $16,166,000. Finally, KLCM Advisors Inc. grew its stake in Pfizer by 75.0% during the fourth quarter. KLCM Advisors Inc. now owns 173,793 shares of the biopharmaceutical company’s stock valued at $5,004,000 after acquiring an additional 74,487 shares in the last quarter. 68.36% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on the stock. BMO Capital Markets restated an “outperform” rating and issued a $36.00 price objective (up from $33.00) on shares of Pfizer in a research report on Thursday, May 2nd. Argus lowered shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $45.00 price target on shares of Pfizer in a research note on Monday, April 15th. Morgan Stanley upped their target price on Pfizer from $28.00 to $29.00 and gave the stock an “equal weight” rating in a research note on Thursday, May 2nd. Finally, Guggenheim started coverage on shares of Pfizer in a report on Friday, February 23rd. They issued a “buy” rating and a $36.00 price objective for the company. Ten analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $35.86.

Pfizer Stock Down 1.8 %

PFE stock traded down $0.51 during midday trading on Monday, hitting $28.07. The company’s stock had a trading volume of 35,545,561 shares, compared to its average volume of 41,873,535. Pfizer Inc. has a 12 month low of $25.20 and a 12 month high of $40.37. The firm’s 50-day moving average is $27.50 and its 200-day moving average is $27.85. The company has a current ratio of 1.05, a quick ratio of 0.78 and a debt-to-equity ratio of 0.66. The company has a market cap of $159.06 billion, a PE ratio of -468.09, a P/E/G ratio of 1.12 and a beta of 0.70.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share for the quarter, beating the consensus estimate of $0.56 by $0.26. Pfizer had a positive return on equity of 8.64% and a negative net margin of 0.56%. The firm had revenue of $14.88 billion for the quarter, compared to analysts’ expectations of $13.87 billion. During the same period in the prior year, the firm earned $1.23 EPS. The company’s revenue was down 19.5% compared to the same quarter last year. On average, equities research analysts forecast that Pfizer Inc. will post 2.38 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 14th. Stockholders of record on Friday, May 10th will be given a dividend of $0.42 per share. The ex-dividend date is Thursday, May 9th. This represents a $1.68 dividend on an annualized basis and a dividend yield of 5.99%. Pfizer’s payout ratio is currently -2,799.53%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.